BioVie Presents New Biomarker Data From ADDRESS-LC Trial Of Bezisterim In Long COVID; Analyses Suggest Single Efficacy Endpoint May Not Adequately Capture Clinically Meaningful Response To Therapeutic Intervention Across Biological Diversity Of Long Covid
Benzinga Newsdesk 1 day ago
NewsBiotechGeneralEvents
New findings from the Phase 2 ADDRESS-LC trial suggest two distinct biomarker-defined Long COVID endotypes1 associated with different patient responses to bezisterim treatment.Patients with a high-inflammatory endotype
New findings from the Phase 2 ADDRESS-LC trial suggest two distinct biomarker-defined Long COVID endotypes1 associated with different patient responses to bezisterim treatment.
Patients with a high-inflammatory endotype showed improvements in objective cognitive impairment, while those with a low-myeloid endotype experienced improvements in fatigue and post-exertional malaise.